alterboy
As with the initial Bifrontera deal which caused a brief, small increase in the pps, getting a smaller portion for 1.8 million US will not have a impact on the pps. First of all it makes no sence dollar wise compared to the old deal. It defintely looks better for DNAP and not Biofrontera. It could be another important brick in the pavement but another PR with no revenue and more shares being handed out is not going to move this stock. You can hear "Hold onto your butts" all day long but the bottom line is DNAP is at the most critical stage in its history right now. If the pps drops below .10 we have all been BURNED.(or burned more)
ice
ps, DNAP just bought out Trace, a new genotyping machine and now a portion of Biofrontera, spend, spend, spend will not get a nickle in your pocket, did you all so not there are still 8 million retricted shares, ouch.